Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2019-08-27 Director's Dealing
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/KRX). It details the share acquisition (장내매수) by an executive (Choi Jun-hee) of Pharmabcine. This type of filing is a standard regulatory disclosure for insider trading/shareholding changes, which corresponds to the 'Director's Dealing' category.
2019-08-27 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. This type of filing is required when an individual or entity acquires a significant stake (typically 5% or more) in a company, or when there is a change in their holdings. In the provided taxonomy, this corresponds to a 'Major Shareholding Notification'.
2019-08-27 Korean
기타경영사항(자율공시)(TTAC-0001의 재발성 교모세포종 다기관 국제 임상 (PMC_TTAC-0001_03)에 대한 호주 2상 임상시험 계획 승인)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure (자율공시) from a Korean biotech company, PharmAbcine, regarding the approval of a Phase 2 clinical trial for their drug candidate TTAC-0001 in Australia. Since this is a specific regulatory announcement regarding clinical trial progress and does not fit into the other specialized categories like financial reports or M&A, it is classified as a general regulatory filing.
2019-08-16 Korean
반기보고서 (2019.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'PharmAbcine' (파멥신) for the period ending June 30, 2019. It contains detailed financial information, business descriptions, capital changes, and management discussions, which are characteristic of a comprehensive interim financial report. It is not a mere announcement or certification, as it includes substantive financial data and operational details. H1 2019
2019-08-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea for reporting insider transactions and changes in share ownership by directors and major shareholders. Based on the provided categories, this aligns with 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2019-08-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by corporate insiders to disclose changes in their shareholdings. This corresponds to the 'Director's Dealing' category, which covers insider trades and changes in ownership by company directors and executives.
2019-07-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.